

Effective July 17, 2001

Reviewed/Revised: 8/2005, 11/1/11, 4/17/12, 5/27/14 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23, 2/8/24, 2/20/25

## INJECTABLE MEDICATION COVERAGE

## **Policy**

VCHCP covers injectable medications when an appropriate oral alternative drug does not exist. This coverage includes those medications intended to be self-administered. The medication must be medically necessary and appropriate to the member's needs or condition.

All injectables except for Insulins, epinephrine, headache medications, medroxyprogesterone acetate and approved immunization products require prior authorization. Additionally, appropriate copay applies as defined by Plan's Pharmacy Benefit Structure.

## **Injectables Not Covered:**

Experimental or investigational drugs or drugs that have not been proven safe and effective for a specific disease or approved for a mode of treatment by the FDA and/or the NIH are not covered. **NOTE**: This provision does not exclude coverage of the "off label" use of otherwise FDA approved prescribed medications.

Drugs related to the treatment of non-covered services are not covered.

Certain classes of injectable medications are not covered:

- 1. Anabolic Steroids When Used for Athletic Performance Enhancement
- 2. Infertility Injectables, unless otherwise approved or required by regulation or covered by a specific benefit design.

#### Procedure:

A treatment authorization request (TAR) must be submitted to UR for approval by the UR physician or Medical Director.

Attachments: None

### **History:**

Reviewers: Richard O. Ashby MD, QA Committee; Date: July 2001



Effective July 17, 2001

Reviewed/Revised: 8/2005, 11/1/11, 4/17/12, 5/27/14 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23, 2/8/24, 2/20/25

Reviewed /Revised: C. Wilhelmy MD & L. Catapang RN; Date: Aug 2005

Committee Review: UM: August 8, 2005; QAC: August 23, 2005

Reviewed/Revised: Albert Reeves MD; Date: 11/1/11

Committee Review: UM Committee on 11/10/11 & QA on 11/22/11

Reviewed/No Updates: Albert Reeves, MD; Date: 4/17/12 Committee Reviews: UM: May 10, 2012; QAC: May 22, 2012 Reviewed/No Updates: Albert Reeves, MD; Date: 1/28/13

Committee Review: UM: February 14, 2013; QAC: February 26, 2013

Reviewed/No Updates: Catherine Sanders, MD

Committee Review: UM: February 13, 2014; QAC: February 25, 2014

Reviewed/Updated: Catherine Sanders, MD

Committee Review: UM: May 8, 2014; QAC: May 27, 2014

Reviewed/No Updates: Catherine Sanders, MD

Committee Review: UM: February 12, 2015: QAC: February 24, 2015

Reviewed/No Updates by: Faustine Dela Cruz, RN & Catherine Sanders, MD

Committee Review: UM: February 11, 2016; QAC: February 23, 2016 Reviewed/Updated: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 9, 2017; QAC: February 28, 2017 Reviewed/Updated: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 8, 2018; QAC: February 27, 2018 Reviewed/No Updates: Catherine Sanders, MD & Robert Sterling, MD Committee Review: UM: February 14, 2019; QAC: February 26, 2019 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 13, 2020; QAC: February 25, 2020 Reviewed/No Updates: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 11, 2021; QAC: February 23, 2021 Reviewed/No Updates by: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 17, 2022; QAC: February 22, 2022 Reviewed/No Updates by: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 2, 2023; QAC: February 7, 2023 Reviewed/No Updates by: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 8, 2024; QAC: February 27, 2024 Reviewed/Updated by: Howard Taekman, MD & Robert Sterling, MD Committee Review: UM: February 20, 2025; QAC: February 25, 2025

## References:



Effective July 17, 2001

Reviewed/Revised: 8/2005, 11/1/11, 4/17/12, 5/27/14 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23, 2/8/24, 2/20/25

- U.S. Pharmacopeial Convention, Inc. USP Dispensing Information. Volume I-- Drug Information for the Health Care Professional, 19th Ed. Englewood, CO: Micromedex, 1999.
- 2. Medical Economics, Inc. Physicians' Desk Reference, 54th Ed. Montvale, NJ: Medical Economics Data Production, 2000.
- 3. Mosby-Yearbook, Inc. Mosby's GenRx: The Complete Reference for Generic and Brand Drugs, 10th Ed. St. Louis, MO: Mosby, 2000.
- 4. American Hospital Formulary Service. AHFS Drug Information 2000. Bethesda, MD: American Society of Health-System Pharmacists, 2000.

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
2/9/17	Yes	Catherine Sanders, MD; Robert Sterling, MD	Annual Review;
			updated to reflect
			addition of
			epinephrine,
			headache
			medications,
			medroxyprogesteron
			e acetate and
			removal of Imitrex –
			as exceptions to
			injectables requiring
			prior authorization
2/8/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual Review
2/14/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual Review
2/13/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/11/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/17/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/2/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/8/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual Review
2/20/25	Yes	Howard Taekman, MD and Robert Sterling, MD	Added "or required
			by regulation or
			covered by a specific
			benefit design" after
			Infertility Injectables,



Effective July 17, 2001

Reviewed/Revised: 8/2005, 11/1/11, 4/17/12, 5/27/14 Reviewed/No Updates: 1/28/13, 2/13/14, 2/12/15, 2/11/16, 2/9/17, 2/8/18, 2/14/19, 2/13/20, 2/11/21, 2/17/22, 2/2/23, 2/8/24, 2/20/25

	<del>_</del>
	unless otherwise
	approved. Removed
	"Notes: All
	injectables except
	for Insulins,
	epinephrine,
	headache
	medications,
	medroxyprogesteron
	e acetate and
	approved
	immunization
	products require
	prior authorization.
	Additionally,
	appropriate copay
	applies as defined by
	Plan's Pharmacy
	Benefit Structure."